Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG
Imaging of T-cell Activation With [18F]F-araG in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Undergoing PD-1/PD-L1 Directed Therapy
Sponsor: CellSight Technologies, Inc.
A PHASE2 clinical study on Advanced Non Small Cell Lung Cancer, this trial is actively recruiting participants. The trial is conducted by CellSight Technologies, Inc. and has accumulated 4 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
4 versions recorded-
Nov 2024 — Present [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2024 — Nov 2024 [monthly]
Not Yet Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE2
-
Nov 2023 — Jul 2024 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- CellSight Technologies, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .